SANUWAVE Health, Inc. (SNWV) stock intrinsic value fair value estimate & owner earnings analysis

SANUWAVE Health sells one product, the UltraMIST wound-care system. It is an FDA-cleared device that delivers low-frequency ultrasound through a fluid mist to chronic and acute wounds, and the treatment is reimbursed under CPT code 97610. The business works like razors and blades. A clinic buys the system, then keeps buying single-use applicators for each treatment. Applicators made up about 58% of 2025 revenue, and the rest came mostly from system sales. At the end of 2025 there were 1,292 active systems in the field. Sales are made primarily in the United States. Revenue grew from $13.0 million in 2021 to $44.1 million in 2025, a 35% rise in 2025 alone, and gross margin is about 77%. Growth has not turned into much cash for shareholders, though. The company used cash every year from 2016 through 2023. It relied on expensive convertible and secured debt and repeated share issuance, and its 2024 financial statements carried a going-concern warning. In September 2025 it refinanced with a JPMorgan-led bank group: a $23.0 million term loan at SOFR plus 3.5%, repaid at about $1.4 million a quarter through September 2029, plus a $5.0 million revolving line that matures in September 2027. After the refinancing, and two years of operating profit, management concluded that the going-concern doubt had been removed. How we measured earnings. We start from operating cash flow and remove working-capital swings. We then deduct stock compensation as a real cost, along with the upkeep part of equipment spending. We also treat interest that was accrued but not paid in cash (later rolled into the old debt) as a real cost. Reported 2025 net income of $11.8 million is not a useful guide. It includes an $8.1 million non-cash gain on warrant and derivative liabilities and a one-time $5.4 million patent sale, and we exclude both, along with a one-time $0.6 million landlord build-out reimbursement. On that basis the business lost about $1.5 million in 2024 and earned about $0.7 million in 2025, roughly $0.08 per share. Per-share history is adjusted for the 1-for-375 reverse split. Stock compensation is the key line. It was $4.9 million in 2025 and $3.1 million in the first half of 2026 alone, which absorbs most of the cash the business generates. The 2025 figure bore $3.7 million of cash interest on the old lender. Interest under the new bank loan is running at about $0.8 million per half-year. At that cost, 2025 would have produced about $2.8 million, or $0.31 per share. The first half of 2026 then weakened. Revenue was flat at $19.4 million against $19.4 million a year earlier, and operating expenses rose from $13.2 million to $16.3 million, turning a $2.0 million operating profit into a $1.4 million loss. H2 is usually stronger (in 2025, $24.7 million of the $44.1 million came in the second half). On a trailing-twelve-month basis, with interest at today's rate, owner earnings are only about $0.6 million. We set the normal level at about $1.5 million a year, between the adjusted 2025 figure and the recent run-rate. We credit no growth: revenue has stalled this year, and wider adoption depends on winning share in a crowded wound-care market, which cannot be counted on. Taxes. The company has about $94.8 million of federal tax losses that do not expire. However, an ownership change in October 2024 limits how much it can use: $4 million a year for five years, then $1.3 million a year. We therefore expect little cash tax through 2029 and some tax afterwards in the stronger cases. Base case, about $1.40 per share. Revenue holds near $44 million, with applicator sales from the installed base and system sales at roughly the recent pace. Owner earnings are about $1.0 million in the first year, reflecting 2026 so far, then $1.5 million a year, easing to about $1.35 million once the tax-loss limit binds after 2029. The installed base and reimbursement code support the business beyond year 10, but nothing in the record shows the product holding its position against competitors for decades. So earnings fade to zero over years 11 to 20. We give no credit for lower interest as the term loan is repaid, because that repayment uses the same cash. Discounted at 6%, this is about $12.8 million, or roughly $1.40 on about 9.1 million diluted shares. Bear case, about -$0.38 per share. The 2026 pattern continues: flat revenue, higher spending and stock compensation around $6 million a year. Owner earnings run at about -$1.0 million a year until the term loan is paid off in 2029, then zero. The 10-K warns that changes to Medicare payment for skin substitutes could squeeze the wound clinics that buy UltraMIST, even though UltraMIST is not a skin substitute itself. At the end of 2025 the company owed $21.6 million on the term loan and $0.7 million on the revolver, against $12.0 million of cash. Cash was $9.4 million by June 30, 2026, and the loan requires about $5.75 million of principal a year and compliance with financial covenants. In this case the business produces nothing to cover that debt, so it appears to owe more than it is worth. Shareholders' claim would be worth about $3.5 million less than nothing, and paying the debt would likely require new shares on poor terms. Bull case, about $3.39 per share. Spending discipline returns 2025's economics: roughly $2.8 million of owner earnings, rising as the loan is repaid on its contractual schedule and interest disappears. After 2029 it settles near $3.0 million once cash taxes start. That level holds through year 10 and fades over the following 15 years. The case credits no revenue growth beyond today's level. What could make this wrong. On the upside, profitable volume growth in applicators, from a larger installed base, without matching increases in sales and stock-compensation costs. On the downside, reimbursement cuts, competition from Arobella, NanoVibronix, SoftWave and larger wound-care companies, or covenant pressure under the bank loan. Investors should also know that the company restated its 2024 results and its first three quarters of 2025. It found unrecorded state sales-tax liabilities and overstated revenue. The filings do not describe the UltraMIST patent position or its expiry dates in detail, so we have not relied on patent protection.